Business Wire

SPLIO

Share
Splio Acquires Tinyclues to Become the European Leader in AI-powered CRM

Splio, CRM expert and developer of the SaaS Individuation® marketing platform, is proud to announce the acquisition of Tinyclues, the specialist in SaaS predictive marketing based on deep learning AI. This acquisition fulfills a shared ambition to enable brands to easily orchestrate large-scale, hyper-personalized marketing plans.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005122/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

On the left, David Bessis (Tinyclues) and on the right, Mireille Messine (Splio) (Photo: Splio)

Splio works with more than 400 brands, including Decathlon, Longchamp and Orange, and has been developing its own Individuation® marketing solution since 2021. Based on machine learning (AI), this solution addresses the dual challenge currently faced within CRM: how to personalize the customer experience for each individual whilst offering marketers a simple solution for large-scale orchestration.

The technological power of the Tinyclues platform increases the value proposition of Splio. A recent winner of both the Sammy and MarTech Breakthrough awards, Tinyclues is currently the most powerful predictive engine on the market, since it is the only one fueled by deep learning. It allows for the automated processing of huge volumes of first-party data for precise customer behaviour prediction. Over 100 brands use Tinyclues on a daily basis, including Veepee, Fnac, Accor, Samsung, Tiffany & Co and SNCF Connect.

The acquisition of Tinyclues thus enables Splio to establish itself as the European leader in AI-powered CRM thanks to its Individuation® marketing software, which can be rapidly and easily deployed across all industries and for companies of all sizes.

AI has become the new standard for better understanding customers and personalizing large-scale marketing communications regardless of industry or business size. Individuation® marketing based on machine learning was an initial response to these challenges. The Tinyclues platform, based on deep learning, strengthens our leadership, and provides new opportunities for sectoral and geographical growth.” Mireille Messine, CEO of Splio.

For a long time, Splio and Tinyclues have shared the same vision of CRM and the same ‘one-to-one at scale’ ambition for clients. Joining Splio enables our deep learning platform to express its full potential by allowing brands to carry out predictive marketing, including customer management and activation.” David Bessis, CEO of Tinyclues.

As a result of this acquisition, Splio now has 250 employees in Europe and the MEA and a portfolio of 500 business clients, from medium-sized companies to large groups from a large range of industries (retail, restaurant, telecoms, travel, hotel, leisure, etc.) with an annual recurring revenue over €30m.

About Splio

Splio is a Martech company headquartered in Paris, with 200 employees, 90 of whom work in Product and R&D, and five offices in Europe and the MEA.

Splio provides a SaaS Individuation® marketing platform to B2C customer marketing professionals. The company has a portfolio of more than 400 brands, from medium-sized enterprises to major groups from four key industries (retail, e-commerce, restaurant and telecom), including Longchamp, Decathlon, Rue du Commerce, Nicolas, Brioche Dorée and Orange.

Splio aims to empower marketing automation with Individuation® enabling companies to activate and engage each of their customers on a case-by-case basis in a unique relationship using AI.

The Individuation® marketing platform is based on a one-of-a-kind innovation that automates each day the most relevant communications to the most appropriate channels for each one of a companies’ customers. The platform is uniquely capable of calculating the optimum based both on a company’s objectives and on the appetencies of each of its customers.

Mireille Messine is the CEO of Splio and Gregory Chapron the Co-CEO. Investors include Sofiouest, Ring Capital, BPI-FAN, Omnes, Seventure, Amundi PEF, BNP Paribas Développement and SWEN.

About Tinyclues

Tinyclues is a Martech company whose precision-AI targets individuals based on buying propensity. Over 100 brands currently use the solution, including Veepee, Fnac, Accor, Samsung, Tiffany & Co and SNCF Connect.

Tinyclues’ cutting-edge technology analyses often-ignored first-party data signals so that CRM teams can accurately predict customer purchase intent and easily orchestrate complex marketing plans.

Tinyclues was the winner of the Sammy Award for Product of the Year in 2021 and the Martech Breakthrough Award for Best CRM Solution for Enterprises in 2021 and 2022. Tinyclues has been listed as a ‘Vendor to Watch’ in Gartner’s Magic Quadrant for Digital Marketing Analytics and as a ‘Cool Vendor’ within its Multichannel Marketing Report. In addition, G2 awarded Tinyclues the ‘Users Love Us’ and ‘High Performer’ certificates in 2021 and 2022.

Tinyclues’ investors include ISAI, Elaia, Alven Capital and EQT Ventures.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005122/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye